Acting Mass. U.S. Attorney: Former Pharmaceutical Sales Representative Sentenced to More Than 4 Years in Prison for Insurance Fraud, Aggravated Identity Theft
An
"
"Today's sentence holds
"Today's sentence shows that fraudsters like
"Working with our law enforcement partners, the
In 2014 and 2015, Moffett, a pharmaceutical sales representative for Aegerion, marketed the company's cholesterol drug Juxtapid. Juxtapid was approved by the FDA only to treat high cholesterol in patients with a rare genetic disease called homozygous familial hypercholesterolemia (HoFH). The FDA approved the drug only to treat HoFH patients because the drug carried serious risks of side effects, including liver damage. The drug's label included a black box warning.
Moffett nonetheless convinced doctors to prescribe Juxtapid, which costs over
Acting
Judicial Council of California Issues Opinion in David Zamora Vs. Security Industry Specialists Case
Allstate to sell Northbrook headquarters after 54 years
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News